ATE555780T1 - Nahrungsergänzungsmittel für metabolische hirnleistungsstörungen - Google Patents

Nahrungsergänzungsmittel für metabolische hirnleistungsstörungen

Info

Publication number
ATE555780T1
ATE555780T1 AT98944644T AT98944644T ATE555780T1 AT E555780 T1 ATE555780 T1 AT E555780T1 AT 98944644 T AT98944644 T AT 98944644T AT 98944644 T AT98944644 T AT 98944644T AT E555780 T1 ATE555780 T1 AT E555780T1
Authority
AT
Austria
Prior art keywords
acid
krebs cycle
dietary supplements
individual
pharmaceutical composition
Prior art date
Application number
AT98944644T
Other languages
English (en)
Inventor
John P Blass
Original Assignee
John P Blass
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by John P Blass filed Critical John P Blass
Application granted granted Critical
Publication of ATE555780T1 publication Critical patent/ATE555780T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Nutrition Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
AT98944644T 1997-10-24 1998-09-01 Nahrungsergänzungsmittel für metabolische hirnleistungsstörungen ATE555780T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6316597P 1997-10-24 1997-10-24
PCT/US1998/018120 WO1999021565A1 (en) 1997-10-24 1998-09-01 Nutritional supplement for cerebral metabolic insufficiencies

Publications (1)

Publication Number Publication Date
ATE555780T1 true ATE555780T1 (de) 2012-05-15

Family

ID=22047375

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98944644T ATE555780T1 (de) 1997-10-24 1998-09-01 Nahrungsergänzungsmittel für metabolische hirnleistungsstörungen

Country Status (7)

Country Link
US (2) US6537969B1 (de)
EP (1) EP1032403B1 (de)
JP (2) JP2001521002A (de)
AT (1) ATE555780T1 (de)
AU (1) AU760140B2 (de)
CA (1) CA2306875C (de)
WO (1) WO1999021565A1 (de)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0804183B1 (de) * 1994-11-08 2006-07-05 Avicenda Group, Inc. Verwendung von kreatin oder kreatinanologen zur behandlung von huntington chorea, morbus parkinson und amyotrophen lateralsklerose
US20050245612A1 (en) * 2004-05-03 2005-11-03 Blass John P Pharmaceutical compositions for metabolic insufficiencies
US20060128671A1 (en) * 1998-04-02 2006-06-15 The General Hospital Corporation Compositions containing a combination of a creatine compound and a second agent
EP1065931A4 (de) * 1998-04-02 2006-10-11 Avicena Group Inc Eine kombination einer kreatin-verbindung und eines zweiten stoffes enthaltende zusammensetzungen
DE19853487A1 (de) 1998-11-19 2000-05-25 Fumapharm Ag Muri Verwendung von Dialkylfumaraten
DE19932197A1 (de) * 1999-07-09 2001-01-18 Neudecker Birgit Topisch anzuwendendes Mittel mit schützender und regenerativer Wirkung
US6689753B1 (en) * 1999-11-05 2004-02-10 Axonyx, Inc. β sheet breaker peptide analogs that inhibit β pleated sheet formation in amyloid β-peptide
DE10000577A1 (de) * 2000-01-10 2001-07-26 Fumapharm Ag Muri Verwendung von Fumarsäurederivaten zur Behandlung mitochondrialer Krankheiten
GB2348371B (en) * 2000-03-14 2001-04-04 Soares Da Silva Patricio Compositions comprising blockers of L-DOPA renal cell transfer for the treatment of Parkinson's disease
US7208180B2 (en) 2000-05-08 2007-04-24 N.V. Nutricia Method and preparation for the preventing and/or treating vascular disorders and secondary disorders associated therewith
US7226916B1 (en) 2000-05-08 2007-06-05 N.V. Nutricia Preparation for the prevention and/or treatment of vascular disorders
CA2776023A1 (en) 2001-01-12 2002-07-18 Fumapharm Ag Fumaric acid amides
JP2004518712A (ja) 2001-02-14 2004-06-24 ラート・マティアス 細胞の生体エネルギー代謝に関与する生化学的化合物の組成物及びそれの使用法
WO2003059387A2 (en) * 2001-12-21 2003-07-24 Ilex Oncology, Inc. Combination comprising anti-cd52 antibodies and other therapeutic agents for treatment for multiple sclerosis
JPWO2003068215A1 (ja) * 2002-02-14 2005-06-02 味の素株式会社 ミトコンドリア病用薬剤
EP1820806A1 (de) * 2006-02-16 2007-08-22 Crossbeta Biosciences B.V. Affinitätsbereiche
DE10217314A1 (de) 2002-04-18 2003-11-13 Fumapharm Ag Muri Carbocyclische und Oxacarboncyclische Fumarsäure-Oligomere
WO2003101402A2 (en) * 2002-06-04 2003-12-11 Avicena Group, Inc. Methods of treating cognitive dysfunction by modulating brain energy metabolism
EP1380290A1 (de) * 2002-07-09 2004-01-14 Universitair Medisch Centrum Utrecht Cross-Beta-Strukturweg und seine therapeutische Relevanz
US20070003552A1 (en) * 2002-07-09 2007-01-04 Gebbink Martijn F B Cross-beta structure comprising amyloid binding proteins and methods for detection of the cross-beta structure, for modulating cross-beta structures fibril formation and for modulating cross-beta structure-mediated toxicity and method for interfering with blood coagulation
CA2494348C (en) 2002-08-01 2014-04-08 Yeda Research And Development Co. Ltd. Method and composition for protecting neuronal tissue from damage induced by elevated glutamate levels
US7977049B2 (en) * 2002-08-09 2011-07-12 President And Fellows Of Harvard College Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms
WO2004028468A2 (en) * 2002-09-27 2004-04-08 Children's Medical Center Corporation Methods and compositions for treatment of neurological disorder
US20060025337A1 (en) * 2003-07-01 2006-02-02 President And Fellows Of Harvard College Sirtuin related therapeutics and diagnostics for neurodegenerative diseases
US20050096256A1 (en) * 2003-07-01 2005-05-05 President And Fellows Of Harvard College Compositions for manipulating the lifespan and stress response of cells and organisms
SE0301947D0 (sv) * 2003-07-01 2003-07-01 Gramineer Internat Ab New method and uses
US20060247207A1 (en) * 2003-07-01 2006-11-02 Pierzynowski Stefan G Use of alpha-ketoglutaric acid for the treatment of malnutrition or high plasma glucose condition
DK1663197T3 (da) 2003-09-09 2008-01-07 Fumapharm Ag Anvendelse af fumarsyrederivater til behandling af hjerteinsuffiens og astma
US8017634B2 (en) 2003-12-29 2011-09-13 President And Fellows Of Harvard College Compositions for treating obesity and insulin resistance disorders
EP1708689A2 (de) 2003-12-29 2006-10-11 The President and Fellows of Harvard College Zusammensetzungen zur behandlung oder verhinderung von adipositas und insulin-resistenten erkrankungen
US20060084085A1 (en) * 2004-06-16 2006-04-20 Sinclair David A Methods and compositions for modulating Bax-mediated apoptosis
PL368572A1 (en) * 2004-06-17 2005-12-27 Sgp & Sons Ab Pharmaceutical compound for prevention and therapy of increased level of cholesterol, ldl and triglycerides as well as application of the pharmaceutical compound as an agent acting against atherosclerosis and used in circulatory system affections
WO2006004722A2 (en) * 2004-06-30 2006-01-12 Biomol Research Laboratories, Inc. Compositions and methods for selectively activating human sirtuins
US20060024385A1 (en) * 2004-07-27 2006-02-02 Pedersen Mark A Metabolic capacity enhancing compositions and methods for use in a mammal
PL369552A1 (pl) * 2004-08-12 2006-02-20 Sgp & Sons Ab Preparat farmaceutyczny lub/i żywieniowy lub/i laboratoryjny wzmagający, wspomagający funkcjonowanie komórek nerwowych i układu nerwowego oraz zastosowanie preparatu farmaceutycznego lub/i żywieniowego w procesie ochrony funkcji układu nerwowego oraz zastosowanie preparatu do ochrony wzrostu stymulacji namnażania i zapobiegania apoptozie komórek nerwowych
KR20070057218A (ko) * 2004-08-30 2007-06-04 가부시키가이샤 가네카 미토콘드리아 활성화제
ES2510690T3 (es) * 2004-12-17 2014-10-21 Alan B. Cash Método para extender la esperanza de vida y retrasar la aparición de enfermedad relacionada con la edad
CN101084003A (zh) * 2004-12-21 2007-12-05 重症救护联络公司 治疗性营养组合物或联合药物及其使用方法
AU2006204699B2 (en) * 2005-01-13 2012-04-26 Sirtris Pharmaceuticals, Inc. Novel compositions for preventing and treating neurodegenerative and blood coagulation disorders
EP1874129A1 (de) * 2005-04-28 2008-01-09 Unilever PLC Peptide mit ace-hemmwirkung
WO2006138418A2 (en) * 2005-06-14 2006-12-28 President And Fellows Of Harvard College Improvement of cognitive performance with sirtuin activators
US20070004639A1 (en) * 2005-07-01 2007-01-04 Bodybio, Inc. Methods and compositions for treating Parkinson's disease
US20070149466A1 (en) * 2005-07-07 2007-06-28 Michael Milburn Methods and related compositions for treating or preventing obesity, insulin resistance disorders, and mitochondrial-associated disorders
EP2386861A3 (de) * 2005-07-13 2012-07-18 Crossbeta Biosciences B.V. Cross-Beta-Struktur-bindende Verbindungen
US20070015133A1 (en) * 2005-07-13 2007-01-18 Umc Utrecht Holding B.V. Method for detecting and/or removing protein and/or peptide comprising a cross-beta structure from an aqueous solution comprising a protein
US8114832B2 (en) * 2005-07-13 2012-02-14 Crossbeta Biosciences B.V. Method for detecting and/or removing a protein comprising a cross-beta structure from a pharmaceutical composition
BRPI0613525A2 (pt) * 2005-07-13 2011-05-31 Crossbeta Biosciences Bv métodos para produzir uma composição imunogênica, para melhorar a imunogenicidade de uma composição, para intensificar a imunogenicidade de uma composição de vacina, e para determinar a quantidade de estruturas beta-cruzadas em uma composição de vacina, usos de estruturas beta-cruzadas, e de uma composição imunogênica, vacina de subunidade, e, composição imunogênica
JP2007023010A (ja) * 2005-07-19 2007-02-01 Toshiro Azegami 閉経後のホルモンバランス調整及びパーキンソン症の予防改善目的の経口組成物
DE102005035917A1 (de) * 2005-07-28 2007-02-01 November Ag Verwendung von Isocitrat, Isocitronensäure oder einem Derivat davon zur Herstellung eines Medikaments
ATE554663T1 (de) 2005-07-29 2012-05-15 Tima Foundation Zusammensetzung zur steuerung des alkohol metabolismus und zur reduktion des risikos von alkoholbedingten krankheiten
US20070292403A1 (en) * 2006-05-11 2007-12-20 Avicena Group, Inc. Methods of treating a neurological disorder with creatine monohydrate
US8435547B2 (en) * 2006-08-30 2013-05-07 John P. Blass Cream for stimulating mitochondrial activity in the skin
HUE032251T2 (en) * 2007-02-08 2017-09-28 Biogen Ma Inc Neuroprotection in demyelinating diseases
EP2653873B8 (de) 2007-02-08 2022-08-24 Biogen MA Inc. Zusammensetzungen und deren Verwendung zur Behandlung von Multipler Sklerose
EP2058001A1 (de) * 2007-11-08 2009-05-13 Crossbeta Biosciences B.V. Steigerung der Immunogenizität von Antigenen
EP2058000A1 (de) * 2007-11-08 2009-05-13 Crossbeta Biosciences B.V. Zur Aktivierung von T-Zellen fähige immunogene Zusammensetzung
US20090269796A1 (en) * 2007-12-05 2009-10-29 The General Hospital Corporation Methods of detecting and treating myocardial ischemia and myocardial infarction
WO2010033045A1 (en) * 2008-09-16 2010-03-25 Igor Anatolievich Pomytkin Compositions and methods for prevention or treatment of beta amyloid deposition
US9233099B2 (en) 2012-01-11 2016-01-12 University Of Cincinnati Methods of treating cognitive dysfunction by modulating brain energy metabolism
PL3398594T3 (pl) 2012-09-19 2024-11-04 Grespo Ab Kompozycje do ulepszenia funkcji mózgu
US20140243400A1 (en) * 2013-02-28 2014-08-28 University of Alaska Anchorage Compositions comprising citric acid and malic acid and methods and uses thereof
US10238673B2 (en) 2013-03-13 2019-03-26 Genetic Disease Investigators, LLC Methods and compositions for treatment of dry eye and correction of organ dysfunctions
CA2940871C (en) 2013-03-13 2020-10-20 Genetic Disease Investigators, LLC Methods and compositions for correction of organ dysfunction
GB201411937D0 (en) 2014-07-03 2014-08-20 Medical Res Council Succinate dehydrogenase inhibitors (SDH's)
JP6831558B2 (ja) * 2016-08-23 2021-02-17 株式会社Ｈｂｃフナト 脳機能改善組成物
CA3037235A1 (en) * 2016-09-22 2018-03-29 Alan B. Cash Method to alleviate the symptoms of pms
JP6129395B1 (ja) * 2016-10-29 2017-05-17 誠一 荒木 ミトコンドリア活性化に起因した血管内皮細胞保護回復用還元型ビタミンｂ２製剤
IT201700087359A1 (it) * 2017-07-28 2019-01-28 Professional Dietetics Spa Composizioni comprendenti amino acidi per l'uso nel trattamento di malattie associate a disfunzione mitocondriale
IT201800006725A1 (it) * 2018-06-27 2019-12-27 Composizioni comprendenti aminoacidi per l'uso nella prevenzione e nel trattamento di malattie epatiche
JP2022504584A (ja) * 2018-10-11 2022-01-13 インブリア ファーマシューティカルズ， インコーポレイテッド Ｔｃａ回路中間体およびその使用方法
US20210369750A1 (en) * 2018-10-24 2021-12-02 Ponce De Leon Health Designated Activity Company Nicotinamide riboside compositions for healthspan extension
IT201900002109A1 (it) 2019-02-13 2020-08-13 Professional Dietetics Spa Composizioni comprendenti amminoacidi per l'uso nel trattamento di lesioni del sistema nervoso centrale
IT202000000442A1 (it) 2020-01-13 2021-07-13 Professional Dietetics Spa Composizioni comprendenti amino acidi per l'uso nella prevenzione e nel trattamento di effetti collaterali della chemioterapia
IT202000000454A1 (it) 2020-01-13 2021-07-13 Professional Dietetics Spa Composizioni comprendenti amino acidi per la prevenzione e il trattamento del cancro
CN114794009A (zh) * 2021-02-05 2022-07-29 崔德斌 一种用于动物模型中诱导癌症的组合物及其用途
CN115212195B (zh) * 2022-06-17 2024-02-27 重庆医科大学 苹果酸在制备预防和/或治疗抑郁症的药物中的用途
US20250221952A1 (en) * 2025-03-14 2025-07-10 Louis Dischler Methods and compositions for large modifications of atp output by inner mitochondrial membrane latching

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3963579A (en) 1973-10-17 1976-06-15 Sanraku-Ocean Co., Ltd. Microbiological process for the production of pepstatins
US4089985A (en) * 1974-11-11 1978-05-16 Wolff H Ezra Papaya juice product and process
DE2502735B2 (de) * 1975-01-23 1978-11-23 J. Pfrimmer & Co, 8520 Erlangen Verwendung von Glycerophosphaten
BE867467A (fr) * 1977-04-11 1978-11-27 Dow Chemical Co Aliments pour animaux contenant de l'acide malique ou un sel de ce dernier
US4975217A (en) * 1981-07-20 1990-12-04 Kimberly-Clark Corporation Virucidal composition, the method of use and the product therefor
US5185161A (en) * 1984-03-21 1993-02-09 Alcide Corporation Disinfection method and composition therefor
DE3537761A1 (de) * 1985-10-24 1987-04-30 Bayer Ag Infusionsloesungen der 1-cyclopropyl-6-fluor-1,4-dihydro-4-oxo-7- (1-piperazinyl)-chinolin-3-carbonsaeure
GB8617482D0 (en) * 1986-07-17 1986-08-28 Geistlich Soehne Ag Pharmaceutical composition
US5210083A (en) * 1986-07-17 1993-05-11 Ed. Geistlich Sohne A.G. Fur Chemische Industrie Pharmaceutical compositions
US5389677B1 (en) * 1986-12-23 1997-07-15 Tristrata Inc Method of treating wrinkles using glycalic acid
CA1336169C (en) 1988-03-01 1995-07-04 Walther Birkmayer Agent for treatment of parkinson's disease
AT397201B (de) 1988-06-03 1994-02-25 Birkmayer Joerg Ddr Verwendung des enzym-cofaktors nadph zur herstellung eines arzneimittels
DE59006184D1 (de) * 1989-05-05 1994-07-28 Asta Medica Ag Salze des Azelastins mit verbesserter Löslichkeit.
US5188861A (en) * 1990-05-31 1993-02-23 Royal Domaine Inc. Process for preparing a dried fruit product
US5380721A (en) * 1990-09-10 1995-01-10 Sterling Winthrop Inc. Aryl-fused and hetaryl-fused-2,4-diazepine and 2,4-diazocine antiarrhythmic agents
US5668117A (en) * 1991-02-22 1997-09-16 Shapiro; Howard K. Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments
GB9215746D0 (en) 1992-07-24 1992-09-09 Hultman Eric A method of increasing creatine supply depot
FR2709982B1 (fr) * 1993-09-15 1995-12-08 Oreal Emulsions acides stables de type huile-dans-eau et compositions les contenant.
JP3645580B2 (ja) 1993-10-22 2005-05-11 株式会社フジモト・ブラザーズ グルコースエステル誘導体を含有する脳代謝改善剤
US5589182A (en) * 1993-12-06 1996-12-31 Tashiro; Renki Compositions and method of treating cardio-, cerebro-vascular and alzheimer's diseases and depression
CN1091604C (zh) * 1995-06-07 2002-10-02 第一制糖株式会社 具有提高了药理作用的加工人参提取物及其制备方法
KR100192678B1 (ko) * 1995-06-07 1999-06-15 손경식 약효가 증강된 가공인삼 제품
PT959888E (pt) * 1996-08-13 2002-02-28 Gerolymatos P N Sa Utilizacao do agente quelante clioquinol para o fabrico de uma composicao farmaceutica para o tratamento de doenca de alzheimer
US20050245612A1 (en) * 2004-05-03 2005-11-03 Blass John P Pharmaceutical compositions for metabolic insufficiencies
FR2777186B1 (fr) * 1998-04-10 2001-03-09 Oreal Utilisation d'au moins un hydroxystilbene dans une composition raffermissante

Also Published As

Publication number Publication date
EP1032403B1 (de) 2012-05-02
WO1999021565A1 (en) 1999-05-06
US6537969B1 (en) 2003-03-25
JP2010189432A (ja) 2010-09-02
CA2306875C (en) 2011-01-04
AU760140B2 (en) 2003-05-08
US20030176365A1 (en) 2003-09-18
EP1032403A1 (de) 2000-09-06
CA2306875A1 (en) 1999-05-06
AU9213998A (en) 1999-05-17
EP1032403A4 (de) 2004-03-31
JP2001521002A (ja) 2001-11-06

Similar Documents

Publication Publication Date Title
EP1032403A4 (de) Nahrungsergänzungsmittel für metabolischen hirnleistungsstörungen
EA200200183A1 (ru) Композиция, содержащая трамадол и противосудорожное лекарственное средство
IN2006KO01346A (de)
IL148103A0 (en) Novel dicarboxylic acid derivatives with pharmaceutical properties
MY142029A (en) Phenoxyacetic acid derivatives
EP3192506A3 (de) Mittel zur prophylaxe/linderung von erwachsenenkrankheiten mit 5-aminolevulinsäure, einem 5-aminolevulinsäure-derivat oder einem 5-aminolevulinsäure-salz oder 5-aminolevulinsäure-derivat als wirkstoff
ZA9610508B (en) Pharmaceutical composition comprising l-carnitine or alkanoyl l-carnitine for the prevention and treatment of diseases brought about by lipid metabolism disorders
HRP20041179B1 (hr) Prekursorski oblici lijekova za aminokiseline s pobuđivačkom aktivnosti
GT199900068A (es) Composiciones solidas que contienen gabapentina y proceso para su preparacion.
BR9811093A (pt) Piridinas substituìdas com 2-amino-6-(4-fenóxi 2-substituìdo)
JP2001521002A5 (de)
RU2012138581A (ru) Органолептически приемлемая пероральная лекарственная форма ибупрофена и способы ее приготовления и применения
BR9915729A (pt) Amidas Èmega de n-arilsulfonil-aminoácido
EP0614456A4 (de) 1alfa,24(s)-dihydroxy vitamin d2, seine synthese und verwendung.
BG103949A (en) A new salt
AU2002224847A1 (en) N-alkylated gaba compounds, processes for their preparation and their use as medicaments
PT1651592E (pt) Novas dibenzo[b,f]oxepino-10-carboxamidas e suas utilizações farmacêuticas
MX2025009410A (es) Formas cristalinas o sales de un compuesto deuterado
GR3006606T3 (de)
DE602005006831D1 (de) Nährmittel und/oder pharmazeutisches präparat für die prophylaxe und behandlung von störungen der spurenelementabsorption aus dem verdauungstrakt
EP3466434A1 (de) Verwendung einer zusammensetzung mit eisenhaltigem aminosäurechelat zur herstellung eines arzneimittels zur reduzierung von milchsäure
UY27570A1 (es) Sal de ácido cítrico de un compuesto terapéutico y composiciones farmacéuticas que la contienen
BR0113814A (pt) Amidas de ácido fenilciclohexanocarboxìlico e sua aplicação
UA66751C2 (en) Benzamides as medicament for treatment of neurodegenerative state, a method for the preparation thereof (variants), pharnaceutical composition for treatment of neurodegenerative states and a method for treatment
BR0116724A (pt) Composto, método de tratamento de um distúrbio neurológico ou de uma doença neurodegenerativa, método de tratamento de dor, composição farmacêutica, uso de um composto, e, processos para a preparação e para a sìntese de um composto